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this method is capable of identifying novel polymorphisms as well
as recognizing polymorphisms that have already been identiﬁed as
informative for distinguishing the various alleles. When fully de-
veloped the method will be two-tiered i.e., capable of resolving
KIR genotypes with locus-speciﬁcity or at an allele-speciﬁc level of
resolution. We present data from previously characterized control
DNA samples and transplant samples using this novel typing
method to demonstrate that the method is capable of accurately
deﬁning KIR genotypes.
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REDUCED INTENSITY PERIPHERAL BLOOD STEM CELL TRANSPLANT
FROM MATCHED RELATED AND UNRELATED DONORS FOR POOR RISK
HEMATOLOGICAL MALIGNANCY
Rossetti, J.M., Lieb, J.V., Shadduck, R.K., Gryn, J.F., Lister, J. West-
ern Pennsylvania Cancer Institute, Pittsburgh, PA.
46 patients with advanced, poor risk hematological malignancy
underwent conditioning with Fludarabine 120 mg/m2, Melphalan
140-180 mg/m2 and Ethyol 910 mg/m2 (FME) followed by periph-
eral blood stem cell transplant (PBSCT) from matched sibling
(sib-allo) (n  25) or matched unrelated donor (MUD) (n  21).
Average age was 46 years (range 19-65). Graft versus host disease
(GVHD) prophylaxis consisted of mycophenolate mofetil 1 gram
q12h through day 35 and dosage adjusted tacrolimus to a target
trough serum level of 5-15 ng/ml through day 90. At 30 days (n 
46) transplant related mortality (TRM) was11%, overall survival
(OS) was 89%, and relapse mortality (RM) was 0%. At 100 days
(n 45) TRM was 40%, OS was 51%, and RM was 9%. The most
frequent causes of death at day 100 were acute GVHD, disease
relapse, and adult respiratory distress syndrome. White blood cell
engraftment was achieved in 98% of patients in an average of 13
days (range 9-21). This engraftment was achieved and maintained
without the use of donor lymphocyte infusion (DLI). One patient
died at day 24 without engrafment. Platelet engraftment was
achieved in 80% of patients in an average of 18 days. In one patient
the platelet count never declined below 20 k/L. Eight patients
died prior to platelet engraftment. All evaluable patients showed
95% donor marrow cells at 100 days after transplant. Acute
GVHD incidence for patients not receiving DLI and alive more
than 30 days after transplant was 56% (grade 2  1, 3  17, 4 
4). For patients more than one year after transplant (n  33) the
OS was 30% (sib-allo  37%, MUD  21%) and disease free
survival was 18% (sib-allo  21%, MUD  14%).
In this aged, heavily pretreated, poor risk group of patients,
reduced intensity PBSCT using FME can yield short-term sur-
vival. This regimen provided rapid and durable engraftment with
full donor hematopoiesis in a majority of patients without the need
for DLI. In an effort to reduce the incidence of acute GVHD and
hopefully TRM, we have added thymoglobulin to the conditioning
regimen at 2 mg/kg/day to be given on days -2, -1, and 0. The
impact on OS, DFS, and chronic GVHD remains to be deter-
mined.
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INTRAVENOUS BUSULFAN VERSUS MELPHALAN-BASED LOW INTEN-
SITY CONDITIONING PRIOR TO ALLOGENEIC STEM-CELL TRANSPLAN-
TATION: LOWER TRM AND A MORE FAVORABLE TOXICITY PROFILE
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus.
Low intensity conditioning (LIC) regimens have been designed
to reduce the toxicity associated with allogeneic stem-cell trans-
plantation (SCT) and to allow SCT in elderly, heavily pretreated
and medically inﬁrm patients. However, the toxicity associated
with some of these regimens is still substantial and it is currently
unknown whether any of the regimens has advantage over the
others. We compared the toxicity and 1-year treatment related
mortality (TRM) following two LIC regimens: ﬂudarabine and
intravenous busulfan (FivBu) (total intravenous Busulfan dose 6.4
mg/kg) and ﬂudarabine and melphalan (FM) (total melphalan dose,
100-140 mg/m2). Fludarabine dose was 125-150 mg/m2 in both
regimens. Ninety-ﬁve patients with various hematologic malignan-
cies (52% chemo-refractory) not eligible for standard condition-
ing, were included in the study. Forty-nine patients (52%) had a
prior autologous SCT. The median age was 52 years (range, 20-66
years). Fifty-three patients had FM and 42 had FivBu. The donor
was an HLA-matched sibling (n  63) or a matched unrelated
donor (n  32). With a median follow-up of 10 months (range,
1-38) 55 patients are alive. Twenty patients (21%) have died due to
TRM. TRM occurred in 4 patients (10%) and 16 patients (30%)
within 1 year following FivBu and FM, respectively. The estimated
Kaplan-Meyer TRM risk was 11  5% and 33  7%, respectively
(p  0.02). The univariant analysis also identiﬁed a prior autolo-
gous SCT within 1 year of the current SCT (p  0.02) and
diagnosis of lymphoma (p  0.05) as risk factors for TRM. Age,
donor source, and chemo-sensitivity were not signiﬁcant. When
these variables were included in a multivariable Cox regression
model the hazard ratios for TRM for patients conditioned with
FM, patients with a prior SCT and patients with lymphoma were
3.2 (1.1-9.6; p 0.04), 2.5 (1.0-6.0; p 0.05) and 2.2 (0.9-5.3; p
0.08), respectively. Severe mucositis and organ dysfunction were
more common after FM, while neutropenia duration was shorter
after FivBu. In conclusion, FivBu has a more favorable toxicity
proﬁle and relatively low TRM as RIC for SCT and may prove to
be the preferred LIC regimen. Disease-speciﬁc studies are required
to assess the impact of different conditioning regimens on relapse
rate, and whether reduction of TRM will translate to better dis-
ease-free survival.
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CYCLOPHOSPHAMIDE, TOTAL BODY IRRADIATION (TBI) AND MAB-
CAMPATH (ALEMTUZUMAB) AS CONDITIONING FOR VOLUNTARY UN-
RELATED DONOR (VUD) HAEMOPOIETIC STEM CELL TRANSPLANTS
(HSCT): THE SCOTTISH EXPERIENCE
Bhandari, S., Walker, M., Holyoake, T., Franklin, I.M., McQuaker,
G., Parker, A.N. Glasgow Royal Inﬁrmary, Glasgow, Scotland, United
Kingdom.
Scotland has a population of approximately 5 million people and
supports a single VUD allograft centre based in Glasgow. We
adopted a conditioning regime consisting of 60 mg/kg cyclophos-
phamide D-6 to D-5, TBI 1440 Gy in 8 fractions D-4 to 0 and
Mabcampath 10 mg D-5 to -1 in year 2000. Data was collected
retrospectively in 9/03 for the 21 VUD HSCT patients (pts)
conditioned with this regime between 4/00 and 4/03. 11 males and
10 females were transplanted for the following diagnoses; 12 AML
(7CR1, 5CR2), 4 ALL (2CR1, 2CR2), 4 MDS and 1 NHL (CR2).
The median age was 31 years (range 17-50). Molecular tissue
typing carried out at the A, B, Cw, DRB1 and DQ loci matched at
all 10 loci in 17 pts. 3 pts mismatched at class 2 (2DRB1;1DQ) and
1 mismatched at 2 loci (DRB1 and Cw). 12 pts received unmodiﬁed
bone marrow median dose 3.2x108 mononuclear cells/kg (range 1
to 6.7x 108) and 9 had peripheral blood stem cells median dose
7x106 CD34/kg (range 1.4 to 12x106). All received short course
methotrexate and cyclosporine as graft versus host disease (GvHD)
prophylaxis, which was tapered from D100 if there was no acute
GvHD. Median follow up was 647 days (range 170 to 1233 days).
The median time to neutrophil engraftment 0.5x109/l was 17 days
(range 13 to 29 days) and platelets 20x 109/l was 17 days (range
11 to 32 days). There were no graft failures. Acute grade II-IV
GvHD occurred in 5 pts (23.8%) with grade II in 3 (14.3%) and
grade III in 2 (9.5%). No grade IV acute GVHD was seen. Of the
5 acute GvHD pts, 1 died of disease relapse, 2 died of post
transplant lymphoproliferative disorder (PTLD), 1 developed
chronic extensive GvHD (grade III pt) and 1 had complete reso-
lution of acute GvHD. Relapse occurred in 5 pts (24%). The D100
transplant related mortality (TRM) was 14.3% and at 3.4 years the
overall survival was 48% and TRMwas 33%. There were 11 (52%)
deaths in total, 4 due to disease relapse, 4 infection, 2 PTLD and
1 haemorrhage.
The incidence of grade II-IV acute GVHD is low supporting the
use of Mabcampath as an effective anti-GvHD agent. The two
cases of PTLD were surprising given that Mabcampath depletes
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